Abstract
Background: Despite active research in ovarian cancer immunotherapy, standard of care for ovarian cancer remains surgery and (neo)adjuvant chemotherapy. Patients often develop secondary resistance to chemotherapy, leading to recurrence. Since most mouse models have had a poor translational efficiency so far, there is a need for new therapy development strategies. We here present a mostly human-based pipeline that we have used for target identification and drug development and testing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
